Effects of Tolvaptan Addition to Furosemide in Normo- and Hyponatremia Patients with Heart Failure and Chronic Kidney Disease Stages G3b-5: A Subanalysis of the K-STAR Study

Background: Tolvaptan increases free water clearance (aquaresis) and thereby improves hyponatremia. Although hyponatremia on admission is common in patients with congestive heart failure (CHF), little is known regarding the response to tolvaptan in those who also have chronic kidney disease (CKD) wi...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	American journal of nephrology 2017-11, Vol.46 (5), p.417-426
Hauptverfasser:	Tominaga, Naoto, Kida, Keisuke, Inomata, Takayuki, Sato, Naoki, Izumi, Tohru, Akashi, Yoshihiro J., Shibagaki, Yugo
Format:	Artikel
Sprache:	eng
Schlagworte:	Administration, Oral Aged Aged, 80 and over Analysis Antidiuretic Hormone Receptor Antagonists - therapeutic use Benzazepines - therapeutic use Cardiac patients Care and treatment Chronic kidney failure Clinical trials Dose-Response Relationship, Drug Drug Therapy, Combination - methods Female Furosemide Furosemide - adverse effects Heart failure Heart Failure - blood Heart Failure - drug therapy Heart Failure - urine Humans Hyponatremia Hyponatremia - blood Hyponatremia - chemically induced Hyponatremia - prevention & control Hyponatremia - urine Kidney diseases Kidney Failure, Chronic - blood Kidney Failure, Chronic - drug therapy Kidney Failure, Chronic - urine Male Original Report: Patient-Oriented, Translational Research Potassium - blood Potassium - urine Prospective Studies Sodium - blood Sodium - urine Sodium Potassium Chloride Symporter Inhibitors - adverse effects Treatment Outcome
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Schreiben Sie den ersten Kommentar!